Inflammatory Bowel Disease · Article 146

How Should Clostridioides difficile Infection Be Managed in Patients With IBD?

C. difficile IBD requires a structured, evidence-based clinical approach. This review summarizes the key diagnostic, management, monitoring and decision points for gastroenterology and hepatology practice.

C. difficile IBD clinical reference — Related free clinical resource: First Principles of Gastroenterology and Hepatology.

C. difficile IBD: practical clinical approach

This page focuses on C. difficile IBD with emphasis on decisions that change patient care, common pitfalls, and the current evidence base.

External guidance for C. difficile IBD

Clinical takeaway: For C. difficile IBD, decisions should integrate current guidelines, patient-specific risk, and the evidence summarized below.

Answer first: Any patient with colonic IBD and new or worsening diarrhea should be evaluated for C. difficile. The 2026 AGA clinical practice update recommends a multistep toxin-based diagnostic strategy and prefers fidaxomicin for an initial episode, with oral vancomycin when fidaxomicin is unavailable or unaffordable; metronidazole should not be used as primary therapy. Importantly, necessary IBD immunosuppression should generally continue while CDI is treated, because uncontrolled IBD also worsens outcomes.

Test flares for CDI

Symptoms and endoscopy cannot reliably distinguish infection from inflammatory flare. Patients with ileostomies or pouches can also develop clinically relevant CDI.

Treat both diseases

Current AGA advice emphasizes concurrent treatment of CDI and active IBD rather than reflexively stopping all immunosuppression.

Plan for recurrence

For at least one CDI recurrence in IBD, microbiome-based therapies should be offered to reduce future recurrence when appropriate.

Practical clinical algorithm

1. Test new/worsening IBD diarrhea with a multistep toxin-based assay.

2. Use fidaxomicin first when feasible; use vancomycin when needed.

3. Hospitalize severe/systemically toxic cases.

4. Continue necessary IBD therapy while treating CDI.

5. If symptoms persist after 48–72 hours, reassess IBD activity and consider CMV.

6. Offer microbiome-based recurrence prevention after recurrent CDI.

Common mistakes to avoid

Treating based on PCR positivity alone without clinical context.
Using metronidazole as routine first-line therapy.
Stopping all IBD immunosuppression automatically.
Failing to retest recurrent diarrhea after recent CDI.
Recommending probiotics as proven CDI prevention in IBD.

Trainee takeaway

In IBD, CDI is not an either/or diagnosis: treat the infection aggressively while continuing to control the underlying inflammatory disease.

Frequently asked questions

Which antibiotic is preferred?

Fidaxomicin is preferred in the 2026 AGA update, with vancomycin as an accepted alternative.

Should biologics be stopped?

Not routinely; necessary immunosuppressive therapy should generally continue.

When should microbiome therapy be considered?

After at least one recurrence, depending on immune status and local availability.

References

1. Thomson ABR. Clinical Pharmacology, Physiology and Pathophysiology: Gastroenterology, Hepatology, and Pancreaticobiliary Disorders. CAPstone Academic Publishers; 2024.

2. Thomson ABR. Guideline-Based Management in Gastroenterology. CAPstone Academic Publishers; 2015.

3. Khanna S, Allegretti JR, Hashash JG, Feuerstadt P. AGA Clinical Practice Update on Management of Clostridioides difficile Infection in IBD. Gastroenterology. 2026. doi:10.1053/j.gastro.2026.03.008.

Educational content only. Clinical decisions should incorporate the individual patient, local resources, product labeling, and the most current applicable guideline or regulatory information.

← Back to Clinical Questions